基于强劲的业绩表现，AngioDynamics上调了2026财年全年指引，现预计营收为3.12亿-3.14亿美元，高于此前预测的3.08亿-3.13亿美元，调整后EBITDA为800万-1000万美元，较此前预测的600万-1000万美元有所提高。

On January 6, 2026, AngioDynamics raised its fiscal 2026 net sales guidance to US$312 million–US$314 million and reported ...

AngioDynamics, Inc. ANGO reported breakeven adjusted earnings per share for second-quarter fiscal 2026, marking an ...

Detailed price information for Angiodynamics Inc (ANGO-Q) from The Globe and Mail including charting and trades.

This presentation should be read in conjunction with the press release discussing the company's operating results and ...

Shares of AngioDynamics were trading at $12.68 as of January 02. Over the last 52-week period, shares are up 34.89%. Given that these returns are generally positive, long-term shareholders should be ...

From a technical perspective, AngioDynamics, Inc. (ANGO) is looking like an interesting pick, as it just reached a key level of support. ANGO's 50-day simple moving average crossed above its 200-day ...

AngioDynamics (ANGO) has been on a downward spiral lately with significant selling pressure. After declining 25% over the ...